Scientists created an innovative mRNA cancer vaccine that tethers IL-12 cytokine to cell membranes, restricting its activity to antigen-presenting cells. This design generates powerful pre-effector T cells that effectively fight tumors while avoiding the severe toxicity of systemic IL-12 treatment. The vaccine overcame checkpoint therapy resistance and prevented cancer metastasis in mouse models, representing a promising advancement in cancer immunotherapy.
